Cognition Therapeutics, Inc. (CGTX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 61K | 0 | 0 | 0 | 0 | 0 | 58K | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | -61K | 0 | 0 | 0 | 0 | 0 | -58K | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | 100% | - | - | - | - | - | - | - |
| Operating Expenses | 8.82M | 13.67M | 6.31M | 13.98M | 13.78M | 10.72M | 14.46M | 14.68M | 14.04M | 15.19M | 14.74M | 11.82M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.7M | 2.52M | 2.6M | 2.5M | 2.99M | 2.57M | 3.07M | 3.1M | 3.49M | 3.59M | 3.08M | 3.32M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 6.12M | 11.15M | 3.77M | 11.48M | 10.79M | 8.15M | 11.39M | 11.58M | 10.55M | 11.6M | 11.67M | 8.5M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.82M | -13.67M | -6.38M | -13.98M | -13.78M | -10.72M | -14.46M | -14.68M | -14.1M | -15.19M | -14.74M | -11.82M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 35.99% | -27.49% | 55.92% | 4.77% | 2.32% | 29.4% | 1.91% | -24.21% | -57.16% | -63.32% | -16.79% | 3.24% |
| EBITDA | -8.82M | -13.61M | -6.31M | -13.92M | -13.73M | -10.65M | -14.39M | -14.61M | -14.04M | -15.12M | -14.68M | -11.76M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 35.78% | -27.77% | 56.13% | 4.75% | 2.24% | 29.56% | 1.96% | -24.29% | -57.57% | -63.67% | -16.83% | 3.27% |
| D&A (Non-Cash Add-back) | 0 | 61K | 61K | 61K | 45K | 71K | 70K | 67K | 58K | 66K | 65K | 61K |
| EBIT | 0 | -3.34M | -4.93M | -6.73M | -8.47M | -7.84M | -9.93M | -7.03M | -9.14M | -8.13M | -6.75M | -4.72M |
| Net Interest Income | 5K | -5K | 0 | -3K | -5K | -5K | -3K | -7K | -10K | -9K | -2K | -6K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | -5K | 5K | 0 | 3K | 5K | 5K | 3K | 7K | 10K | 9K | 2K | 6K |
| Other Income/Expense | 0 | 10.33M | 1.45M | 7.24M | 5.29M | 2.88M | 4.53M | 7.64M | 4.95M | 7.05M | 8M | 7.09M |
| Pretax Income | 0 | -3.34M | -4.93M | -6.73M | -8.48M | -7.84M | -9.94M | -7.04M | -9.15M | -8.14M | -6.75M | -4.73M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | - | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | 0 | -3.34M | -4.93M | -6.73M | -8.48M | -7.84M | -9.94M | -7.04M | -9.15M | -8.14M | -6.75M | -4.73M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 100% | 57.37% | 50.39% | 4.36% | 7.33% | 3.67% | -47.24% | -48.98% | -48.27% | -57.1% | -1.87% | 17.84% |
| Net Income (Continuing) | 0 | -3.34M | -4.93M | -6.73M | -8.48M | -7.84M | -9.94M | -7.04M | -9.15M | -8.14M | -6.75M | -4.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.05 | -0.04 | -0.06 | -0.11 | -0.14 | -0.17 | -0.25 | -0.18 | -0.27 | -0.26 | -0.22 | -0.16 |
| EPS Growth % | 64.29% | 77.88% | 74.72% | 38.89% | 48.15% | 34.62% | -13.64% | -12.5% | -125% | -168.42% | -711.81% | 36% |
| EPS (Basic) | -0.05 | -0.04 | -0.06 | -0.11 | -0.14 | -0.17 | -0.25 | -0.18 | -0.27 | -0.26 | -0.22 | -0.16 |
| Diluted Shares Outstanding | 89.19M | 88.9M | 77.95M | 63.69M | 61.83M | 46.43M | 40.42M | 40.06M | 33.74M | 30.78M | 30.37M | 29.61M |
| Basic Shares Outstanding | 89.19M | 88.9M | 77.95M | 63.69M | 61.83M | 46.43M | 40.42M | 40.06M | 33.74M | 30.78M | 30.37M | 29.61M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |